OncoMatch/Clinical Trials/NCT06207799
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Is NCT06207799 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for multiple myeloma.
Treatment: Elranatamab · Lenalidomide · Plerixafor · Melphalan · Busulfan · G-CSF — To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 17p13 deletion
Presence of a high-risk chromosomal abnormality (HRCA) including: 17p13 deletion
Required: IGH t(4;14)
Presence of a high-risk chromosomal abnormality (HRCA) including: t(4;14)
Required: IGH t(14;16)
Presence of a high-risk chromosomal abnormality (HRCA) including: t(14;16)
Required: IGH t(14;20)
Presence of a high-risk chromosomal abnormality (HRCA) including: t(14;20)
Required: CKS1B gain or amplification 1q
Presence of a high-risk chromosomal abnormality (HRCA) including: Gain or amplification 1q by FISH
Prior therapy
Must have received: induction therapy
Participants with disease response PR to induction therapy
Cannot have received: systemic anti-myeloma therapy
Exception: within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug
Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug.
Lab requirements
Kidney function
Estimated creatinine clearance 40 mL/min
Liver function
total bilirubin 1.5X ULN; ALT 2.5 X ULN
Adequate liver function (total bilirubin 1.5X ULN; ALT 2.5 X ULN) Estimated creatinine clearance 40 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify